Log in to save to my catalogue

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e955ede30f6c4f9ea14e0090bdf6615d

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer's disease (AD).
In this randomized, double-blind, placebo-controlled phase III study, we investig...

Alternative Titles

Full title

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e955ede30f6c4f9ea14e0090bdf6615d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e955ede30f6c4f9ea14e0090bdf6615d

Other Identifiers

ISSN

1758-9193

E-ISSN

1758-9193

DOI

10.1186/s13195-017-0318-y